Human epidermal growth factor receptor 2 (HER2) plays a role as an oncogene in several solid organ cancers, including breast, lung and ovarian cancer, and has been successfully used as a therapeutic target (i.e., trastuzumab). The gene discussed is ERBB2; the disease is ovarian carcinoma.